Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 16 de 16
Filtrar
1.
Diabetes Obes Metab ; 17(1): 98-101, 2015 Jan.
Artigo em Inglês | MEDLINE | ID: mdl-25238025

RESUMO

The sodium-dependent glucose transporter 2 (SGLT2) inhibitor remogliflozin etabonate (RE) was evaluated in a 12-week, double-blind, randomized, placebo- and active-controlled, parallel-group study. A total of 252 newly diagnosed and drug-naïve people with type 2 diabetes and glycated haemoglobin (HbA1c) concentrations of 7.0-≤9.5% (53-80 mmol/mol) were recruited. Participants were randomized to RE (100, 250, 500 or 1000 mg once daily or 250 mg twice daily), placebo or 30 mg pioglitazone once daily. The primary endpoint was change in HbA1c concentration from baseline. Secondary endpoints included changes in fasting plasma glucose, body weight and lipid profiles, safety and tolerability. We observed a statistically significant trend in the RE dose-response relationship for change from baseline in HbA1c at week 12 (p < 0.047). RE was generally well tolerated and no effects on LDL cholesterol were observed.


Assuntos
Diabetes Mellitus Tipo 2/tratamento farmacológico , Glucosídeos/administração & dosagem , Hiperglicemia/prevenção & controle , Hipoglicemiantes/administração & dosagem , Moduladores de Transporte de Membrana/administração & dosagem , Pró-Fármacos/administração & dosagem , Pirazóis/administração & dosagem , Inibidores do Transportador 2 de Sódio-Glicose , Estudos de Coortes , Diabetes Mellitus Tipo 2/sangue , Relação Dose-Resposta a Droga , Método Duplo-Cego , Esquema de Medicação , Seguimentos , Glucosídeos/efeitos adversos , Glucosídeos/uso terapêutico , Hemoglobinas Glicadas/análise , Humanos , Hipoglicemiantes/efeitos adversos , Hipoglicemiantes/uso terapêutico , Análise de Intenção de Tratamento , Moduladores de Transporte de Membrana/efeitos adversos , Moduladores de Transporte de Membrana/uso terapêutico , Pessoa de Meia-Idade , Pacientes Desistentes do Tratamento , Pioglitazona , Pró-Fármacos/efeitos adversos , Pró-Fármacos/uso terapêutico , Pirazóis/efeitos adversos , Pirazóis/uso terapêutico , Tiazolidinedionas/administração & dosagem , Tiazolidinedionas/efeitos adversos , Tiazolidinedionas/uso terapêutico , Redução de Peso/efeitos dos fármacos
8.
Calif Med ; 107(5): 406-12, 1967 Nov.
Artigo em Inglês | MEDLINE | ID: mdl-6083246

RESUMO

Treadmill stress testing has many applications in the overall evaluation of ischemic heart disease, both as a diagnostic aid and as an aid in serially following patients under study. Its use in the evaluation of procedures designed to improve myocardial function and coronary perfusion is of great value, for it can supply objective evidence without recourse to more difficult procedures such as determination of blood lactate levels. Ancillary procedures which may complement treadmill stress testing may prove to be valuable additions to the study of ischemic heart disease. The reported high rate of false-positive Master two-step tests would tend to make the treadmill exercise test more attractive.


Assuntos
Doença das Coronárias/diagnóstico , Teste de Esforço , Adulto , Eletrocardiografia , Humanos
9.
Calif Med ; 109(5): 363-7, 1968 Nov.
Artigo em Inglês | MEDLINE | ID: mdl-5726242

RESUMO

In a group of clinically normal male executives subjected to maximal treadmill stress testing, the occurrence of ischemic st segment responses was in all cases unaccompanied by pain, while in a clinically suspect group a large proportion of those having ischemic st segment responses did not have chest pain. While a significant number of persons have no subjective sensation of pain while having ischemic st segment changes on the electrocardiograph during or after maximal treadmill exercise, occasionally atypical pain may occur during or following exercise. Maximal treadmill stress testing is useful in discovering "silent" coronary artery disease.


Assuntos
Doença das Coronárias/diagnóstico , Esforço Físico , Adolescente , Adulto , Idoso , Criança , Eletrocardiografia , Teste de Esforço , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Dor/etiologia
10.
Calif Med ; 116(2): 81-2, 1972 Feb.
Artigo em Inglês | MEDLINE | ID: mdl-18730694
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA